

AMENDMENT TRANSMITTAL LETTER			DOCKET NUMBER: P-UW 3570	
SERIAL NO: 09/323,738	FILING DATE: June 1, 1999	EXAMINER: F. Vander Vegt	GROUP ART UNIT: 1644	
INVENTION: COMPOSITIONS AND METHODS FOR TREATING DIABETES				

TO COMMISSIONER FOR PATENTS



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on December 4, 2000.

By: David A. Gay  
David A. Gay, Reg. No. 39,200  
December 4, 2000  
Date of Signature

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

Transmitted herewith is a Response to the Office Action mailed October 3, 2000, in the above-identified application.

- ☒ Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.
- ☒ Petition for One-month Extension of Time is enclosed (in duplicate).
- ☒ No additional claims fee is required.
- ☐ An additional claims fee is required and has been calculated as shown below:

CLAIMS AS AMENDED

	NUMBER AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		NUMBER OF EXTRA CLAIMS PRESENTED		RATE		FEE	
							SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
TOTAL CLAIMS	40	-	40	-	0	x	\$9	\$18	= \$0	\$
INDEPENDENT CLAIMS	4	-	4	-	0	x	\$40	\$80	= \$0	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			<input type="checkbox"/> YES		<input checked="" type="checkbox"/> NO		\$135	\$270	= \$0	\$
							TOTAL ADDITIONAL FEE		\$0	\$

\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

\*\* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

\*\*\* If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 0, write "0" in the space.


☐ Please charge my Deposit Account No. 03-0370 the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.

☒ A check in the amount of \$55.00 is enclosed, which covers the fee for a one-month extension of time.

Inventors: Osborne and Ramesh  
Serial No.: 09/323,738  
Filed: June 1, 1999  
Page 2

- X The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- X Any additional filing fees required under 37 C.F.R. 1.16.
- X Any patent application processing fees under 37 C.F.R. 1.17.
- X The Commissioner is hereby authorized to charge to Deposit Account No. 03-0370 any fees under 37 CFR 1.17 which may be required under 37 CFR 1.136(a)(3) for an extension of time in any concurrent or future reply requiring a petition for extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

  
\_\_\_\_\_  
David A. Gay  
Registration No. 39,200  
CAMPBELL & FLORES LLP  
4370 La Jolla Village Drive  
7<sup>th</sup> Floor  
San Diego, California 92122  
858-535-9001  
**USPTO CUSTOMER NO. 23601**



1644 / \$

PATENT

Our Docket: P-UW 3570

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of )  
Osborne and Ramesh )  
Serial No: 09/323,738 )  
Filed: June 1, 1999 )  
For: COMPOSITIONS AND METHODS )  
FOR TREATING DIABETES )

Group Art Unit: 1644

Examiner: F. Vander Vegt

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C., 20231 on December 4, 2000.

By:

David A. Gay, Reg. No. 39,200

December 4, 2000

Date of Signature

Commissioner for Patents  
Washington, D.C. 20231

\$ 9  
Harry  
Dec. 23, 00

RESPONSE TO RESTRICTION REQUIREMENT

Responsive to the Office Action mailed October 3, 2000, consideration of the following Remarks is respectfully requested.

REMARKS

Claims 1-40 are pending in the above-identified application and are subject to a restriction requirement under 35 U.S.C. § 121. The Office Action mailed October 3, 2000, alleges that the claims are directed to two independent inventions and restriction to one of the inventions for prosecution is required. The two alleged inventions have been set forth in the Office Action as follows:

Group I: Claims 1-16 and 40, directed to isolated cells comprising a single retroviral expression vector, and a method for producing an isolated population of insulin-secreting cells comprising a three gene vector;